Tionlab Therapeutics develops long-acting injection systems for drug delivery, specifically targeting patients with diabetes and cancer. By enabling monthly injections, the company provides a more convenient method for medication administration, improving patient adherence and quality of life.
Funding
Funding not disclosed
Founders
Product
Problem
Many patients, particularly those with chronic conditions like diabetes and cancer, face challenges adhering to complex medication schedules, leading to suboptimal treatment outcomes and reduced quality of life. Frequent injections can be inconvenient, painful, and contribute to poor adherence.
Solution
Tionlab Therapeutics is developing long-acting injectable drug delivery systems designed to improve patient adherence and quality of life. Their platform technology enables the sustained release of therapeutic agents over extended periods, potentially reducing the frequency of injections to once a month. This approach aims to provide a more convenient and consistent method of medication administration, leading to better therapeutic outcomes for patients with diabetes, cancer, and other chronic diseases. The company focuses on both novel drug development and innovative drug delivery technologies.
Target Audience
The primary target audience includes patients with chronic diseases such as diabetes and cancer, as well as healthcare providers seeking to improve treatment adherence and outcomes.
Features
- Platform technology for long-acting injectable formulations
- Targeted drug delivery systems for enhanced efficacy and reduced side effects
- Focus on improving patient adherence to medication regimens
- Development of sustained-release formulations for monthly injections
- New drug development for diabetes and cancer treatment